Improvement of psoriasis in patients with and without prior biologic experience: Subanalysis of a brodalumab (AMG 827) phase 2 study for moderate to severe plaque psoriasis - 09/05/15
Kim Papp, K. Papp Clinical Research and Probity Medical Research, Waterloo, Ontario, Canada; Alan Menter, Baylor University Medical Center, Dallas, TX, United States; Bruce Strober, University of Connecticut School of Medicine and Probity Medical Research, Farmington, CT, United States; Greg Kricorian, Amgen Inc, Thousand Oaks, CA, United States; Elizabeth H. Z. Thompson, InterMune, Brisbane, CA, United States; Cassandra E. Milmont, Amgen Inc, Thousand Oaks, CA, United States; Ajay Nirula, Amgen Inc, Thousand Oaks, CA, United States; Paul Klekotka, Amgen Inc, Thousand Oaks, CA, United States
Le texte complet de cet article est disponible en PDF.| Amgen Inc funded this study. |
Vol 72 - N° 5S1
P. AB238 - mai 2015 Retour au numéro
Article précédent
- Impact of smoking on response to systemic treatment in patients with psoriasis: A retrospective case-control study
- Intermittent and desintensification adalimumab therapy for moderate to severe psoriasis in clinical practice
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?